SCHEMBL2907710

SCHEMBL2907710

COc1cc2nc(-c3ccc(F)c(Cl)c3)nc(N)c2cc1OCCCN1CCOCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 12/20 0.61
KDR P35968 3/20 0.61
ERBB2 P04626 2/20 0.61
AXL P30530 2/20 0.61
FLT4 P35916 2/20 0.61
MAPT P10636 2/20 0.61
BRAF P15056 2/20 0.61
RET P07949 2/20 0.61
CIT O14578 1/20 0.61
GAK O14976 1/20 0.61
EPHB6 O15197 1/20 0.61
ABCC4 O15439 1/20 0.61
DAPK3 O43293 1/20 0.61
RIPK2 O43353 1/20 0.61
NR1I2 O75469 1/20 0.61
RPS6KA4 O75676 1/20 0.61
STK17B O94768 1/20 0.61
STK10 O94804 1/20 0.61
PRKD3 O94806 1/20 0.61
ABCB11 O95342 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30564570 1.00 EGFR (0.61) EGFRKDRERBB2AXLFLT4
SCHEMBL28959198 0.93 EGFR (0.56) EGFRKDRERBB2AXLFLT4
SCHEMBL30017307 0.93 EGFR (0.56) EGFRKDRERBB2AXLFLT4
SCHEMBL30505601 0.89 EGFR (0.48) EGFRKDRERBB2AXLFLT4
SCHEMBL29229361 0.89 EGFR (0.48) EGFRKDRERBB2AXLFLT4
SCHEMBL28959164 0.87 MAPT (0.52) EGFRKDRERBB2AXLFLT4
SCHEMBL28454175 0.87 EGFR (0.49) EGFRKDRERBB2AXLFLT4
SCHEMBL30017042 0.86 MAPT (0.51) EGFRKDRERBB2AXLFLT4
SCHEMBL28959200 0.86 MAPT (0.51) EGFRKDRERBB2AXLFLT4
SCHEMBL28959171 0.86 ALDH1A1 (0.56) EGFRKDRAXLMAPTRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023194414-A1 POLYDOPAMINE CO-POLYMER NANOPARTICLES CAMBRIDGE ENTERPRISE LIMITED (GB) 2023-10-12 WO disclosed
US-9938268-B2 C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2018-04-10 US disclosed
EP-2367822-B1 TRICYCLIC AZAINDOLES MERCK PATENT GMBH (DE) 2016-10-05 EP disclosed
EP-2367821-B1 C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2015-09-16 EP disclosed
US-8853391-B2 Tricyclic azaindoles MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2485727-A2 PYRROLOPYRAZOLES FOR TREATING CNS DISORDERS Afraxis, Inc. (US) 2012-08-15 EP disclosed
US-20110312951-A1 C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof MERCK PATENT GMBH (DE) 2011-12-22 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
EP-2254889-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF Merck Patent GmbH (DE) 2010-12-01 EP disclosed
EP-1656347-B1 SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2010-10-13 EP disclosed
EP-2010496-B1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-08-25 EP disclosed
WO-2010080253-A1 TRICYCLIC AZAINDOLES MERCK PATENT GMBH (DE) 2010-07-15 WO disclosed
WO-2010077530-A1 C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2010-07-08 WO disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed
EP-1601673-B1 FUSED HETEROCYCLES AND USES THEREOF ASTRAZENECA AB (SE) 2009-06-10 EP disclosed
EP-2010496-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS AstraZeneca AB (SE) 2009-01-07 EP disclosed
EP-1622620-B1 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-02-20 EP disclosed
WO-2007119046-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312951-A1 C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof PRKCB, PNCK, PACSIN2 EGFR 1534/4885KDR 1942/4885ERBB2 330/4885
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 EGFR 815/4885KDR 1368/4885ERBB2 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.